The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma.
D. Ilson
Research Funding - Bayer; Bristol-Myers Squibb; Genentech; Sanofi
Y. Y. Janjigian
No relevant relationships to disclose
M. A. Shah
No relevant relationships to disclose
D. P. Kelsen
No relevant relationships to disclose
L. H. Tang
No relevant relationships to disclose
J. Campbell
No relevant relationships to disclose
L. Fuqua
No relevant relationships to disclose
M. Capanu
No relevant relationships to disclose